

Carlo Bruno Giorda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4650393/publications.pdf>

Version: 2024-02-01

114
papers

3,691
citations

126708

33
h-index

161609

54
g-index

115
all docs

115
docs citations

115
times ranked

5218
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	5.5	231
2	Incidence of Coronary Heart Disease in Type 2 Diabetic Men and Women: Impact of microvascular complications, treatment, and geographic location. <i>Diabetes Care</i> , 2007, 30, 1241-1247.	4.3	144
3	Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. <i>Trials</i> , 2007, 8, 21.	0.7	140
4	Serum Uric Acid and Risk of CKD in Type 2 Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1921-1929.	2.2	136
5	Sex Disparities in the Quality of Diabetes Care: Biological and Cultural Factors May Play a Different Role for Different Outcomes: A cross-sectional observational study from the AMD Annals initiative. <i>Diabetes Care</i> , 2013, 36, 3162-3168.	4.3	102
6	Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients. <i>Stroke</i> , 2007, 38, 1154-1160.	1.0	98
7	Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. <i>Diabetes Care</i> , 2016, 39, 2278-2287.	4.3	93
8	Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. <i>American Heart Journal</i> , 2015, 169, 631-638.e7.	1.2	88
9	Sexual Dysfunction at the Onset of Type 2 Diabetes: The Interplay of Depression, Hormonal and Cardiovascular Factors. <i>Journal of Sexual Medicine</i> , 2014, 11, 2065-2073.	0.3	83
10	Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study. <i>Acta Diabetologica</i> , 2015, 52, 845-853.	1.2	79
11	Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature. <i>Endocrine</i> , 2014, 46, 406-419.	1.1	73
12	Recurrence of Cardiovascular Events in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2154-2159.	4.3	71
13	Variability in $\langle\text{HbA1c}\rangle$, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1570-1578.	2.2	70
14	The Burden of NAFLD and Its Characteristics in a Nationwide Population with Type 2 Diabetes. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-9.	1.0	68
15	Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. <i>Endocrine</i> , 2015, 48, 461-471.	1.1	67
16	Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 736-743.	1.1	67
17	Baseline Quality-of-Care Data From a Quality-Improvement Program Implemented by a Network of Diabetes Outpatient Clinics. <i>Diabetes Care</i> , 2008, 31, 2166-2168.	4.3	61
18	Determinants of Quality in Diabetes Care Process. <i>Diabetes Care</i> , 2009, 32, 1986-1992.	4.3	58

#	ARTICLE	IF	CITATIONS
19	Four-year impact of a continuous quality improvement effort implemented by a network of diabetes outpatient clinics: the AMD Annals initiative. <i>Diabetic Medicine</i> , 2010, 27, 1041-1048.	1.2	55
20	Polyphenol intake and cardiovascular risk factors in a population with type 2 diabetes: The TOSCA.IT study. <i>Clinical Nutrition</i> , 2017, 36, 1686-1692.	2.3	52
21	Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. <i>Nephrology Dialysis Transplantation</i> , 2014, 29, 657-662.	0.4	49
22	Predictors of chronic kidney disease in type 2 diabetes. <i>Medicine (United States)</i> , 2016, 95, e4007.	0.4	48
23	Diabetic kidney disease in the elderly: prevalence and clinical correlates. <i>BMC Geriatrics</i> , 2018, 18, 38.	1.1	47
24	The Impact of Adherence to Screening Guidelines and of Diabetes Clinics Referral on Morbidity and Mortality in Diabetes. <i>PLoS ONE</i> , 2012, 7, e33839.	1.1	45
25	Sex differences in food choices, adherence to dietary recommendations and plasma lipid profile in type 2 diabetes – The TOSCA.IT study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2016, 26, 879-885.	1.1	43
26	Addition of either pioglitazone or a sulfonylurea in type 2 diabetic patients inadequately controlled with metformin alone: Impact on cardiovascular events. A randomized controlled trial. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 997-1006.	1.1	42
27	Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of renal and cardiovascular risk in) Tj ETQq1 1 0.784314 BT / Overlock 10	1.1	41
28	Achievement of therapeutic targets in patients with diabetes and chronic kidney disease: insights from the Associazione Medici Diabetologi Annals initiative. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1526-1533.	0.4	39
29	Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. <i>Atherosclerosis</i> , 2019, 285, 40-48.	0.4	39
30	Age- and Gender-Related Differences in LDL-Cholesterol Management in Outpatients with Type 2 Diabetes Mellitus. <i>International Journal of Endocrinology</i> , 2015, 2015, 1-8.	0.6	38
31	Ten-year comparative analysis of incidence, prognosis, and associated factors for dialysis and renal transplantation in type 1 and type 2 diabetes versus non-diabetes. <i>Acta Diabetologica</i> , 2018, 55, 733-740.	1.2	38
32	Dietary intake and major food sources of polyphenols in people with type 2 diabetes: The TOSCA.IT Study. <i>European Journal of Nutrition</i> , 2018, 57, 679-688.	1.8	38
33	Factors Associated with Beta-Cell Dysfunction in Type 2 Diabetes: The BETADECLINE Study. <i>PLoS ONE</i> , 2014, 9, e109702.	1.1	37
34	Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 111-115.	5.5	36
35	Trends over 8 years in quality of diabetes care: results of the AMD Annals continuous quality improvement initiative. <i>Acta Diabetologica</i> , 2015, 52, 557-571.	1.2	36
36	The impact of diabetes mellitus on healthcare costs in Italy. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 709-719.	0.7	34

#	ARTICLE	IF	CITATIONS
37	Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections. Results of the HYPOS-1 study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2017, 27, 209-216.	1.1	34
38	Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. <i>Journal of Thrombosis and Haemostasis</i> , 2007, 5, 2197-2203.	1.9	32
39	Gender-Disparities in Adults with Type 1 Diabetes: More Than a Quality of Care Issue. A Cross-Sectional Observational Study from the AMD Annals Initiative. <i>PLoS ONE</i> , 2016, 11, e0162960.	1.1	31
40	Natural history and risk factors for diabetic kidney disease in patients with T2D: lessons from the AMD-annals. <i>Journal of Nephrology</i> , 2019, 32, 517-525.	0.9	30
41	$\hat{\pm}$ 1-blocker doxazosin improves peripheral insulin sensitivity in diabetic hypertensive patients. <i>Metabolism: Clinical and Experimental</i> , 1995, 44, 673-676.	1.5	29
42	The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study. <i>Diabetic Medicine</i> , 2004, 21, 738-745.	1.2	29
43	Predictors of early-stage left ventricular dysfunction in type 2 diabetes: results of DYDA study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2011, 18, 415-423.	3.1	28
44	Analysis of midwall shortening reveals high prevalence of left ventricular myocardial dysfunction in patients with diabetes mellitus: the DYDA study. <i>European Journal of Preventive Cardiology</i> , 2012, 19, 935-943.	0.8	28
45	Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. <i>Journal of Hypertension</i> , 2016, 34, 2090-2098.	0.3	28
46	Overall Quality of Care Predicts the Variability of Key Risk Factors for Complications in Type 2 Diabetes: An Observational, Longitudinal Retrospective Study. <i>Diabetes Care</i> , 2019, 42, 514-519.	4.3	28
47	Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: The DEMAND Study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2010, 20, 110-116.	1.1	27
48	The SUBITO-DE study: sexual dysfunction in newly diagnosed type 2 diabetes male patients. <i>Journal of Endocrinological Investigation</i> , 2013, 36, 864-8.	1.8	27
49	Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMD Annals initiative. <i>Diabetes/Metabolism Research and Reviews</i> , 2017, 33, e2873.	1.7	26
50	Correlates of total homocysteine plasma concentration in type 2 diabetes. <i>European Journal of Clinical Investigation</i> , 2004, 34, 197-204.	1.7	25
51	Metabolic syndrome, serum uric acid and renal risk in patients with T2D. <i>PLoS ONE</i> , 2017, 12, e0176058.	1.1	25
52	Ezetimibe + simvastatin versus doubling the dose of simvastatin in high cardiovascular risk diabetics: a multicenter, randomized trial (the LEAD study). <i>Cardiovascular Diabetology</i> , 2010, 9, 20.	2.7	24
53	Effects of doxazosin, a selective $\hat{\pm}$ 1-inhibitor, on plasma insulin and blood glucose response to a glucose tolerance test in essential hypertension. <i>Metabolism: Clinical and Experimental</i> , 1993, 42, 1440-1442.	1.5	23
54	Hospitalisation for heart failure and mortality associated with dipeptidyl peptidase 4 (DPP-4) inhibitor use in an unselected population of subjects with type 2 diabetes: a nested case-control study. <i>BMJ Open</i> , 2015, 5, e007959-e007959.	0.8	23

#	ARTICLE	IF	CITATIONS
55	Sexual Dysfunction in Type 2 Diabetes at Diagnosis: Progression over Time and Drug and Non-Drug Correlated Factors. PLoS ONE, 2016, 11, e0157915.	1.1	23
56	Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Scientific Reports, 2017, 7, 3313.	1.6	23
57	Long-term blood pressure variability and development of chronic kidney disease in type 2 diabetes. Journal of Hypertension, 2019, 37, 805-813.	0.3	23
58	Occurrence over time and regression of nonalcoholic fatty liver disease in type 2 diabetes. Diabetes/Metabolism Research and Reviews, 2017, 33, e2878.	1.7	22
59	Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 419-426.	1.2	22
60	Mild hyperhomocysteinemia, C677T polymorphism on methylenetetrahydrofolate reductase gene and the risk of macroangiopathy in type 2 diabetes: a prospective study. Acta Diabetologica, 2011, 48, 95-101.	1.2	21
61	Resistant Hypertension, Time-Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus. Journal of the American Heart Association, 2017, 6, .	1.6	21
62	Trend over time in hepatic fibrosis score in a cohort of type 2 diabetes patients. Diabetes Research and Clinical Practice, 2018, 135, 65-72.	1.1	21
63	The impact of second-level specialized care on hospitalization in persons with diabetes: a multilevel population-based study. Diabetic Medicine, 2006, 23, 377-383.	1.2	20
64	Recommendations for the implementation of international standardization of glycated hemoglobin in Italy. Clinical Chemistry and Laboratory Medicine, 2010, 48, 623-626.	1.4	20
65	A systematic review of acute pancreatitis as an adverse event of type 2 diabetes drugs: from hard facts to a balanced position. Diabetes, Obesity and Metabolism, 2014, 16, 1041-1047.	2.2	20
66	Prevalence, incidence and associated comorbidities of treated hypothyroidism: an update from a European population. European Journal of Endocrinology, 2017, 176, 533-542.	1.9	20
67	Italian Association of Clinical Endocrinologists (AME) & Italian Association of Clinical Diabetologists (AMD) Position Statement. Endocrine, 2015, 49, 339-352.	1.1	19
68	Apparent Treatment Resistant Hypertension, Blood Pressure Control and the Progression of Chronic Kidney Disease in Patients with Type 2 Diabetes. Kidney and Blood Pressure Research, 2018, 43, 422-438.	0.9	19
69	Association of physicians' accuracy in recording with quality of care in cardiovascular medicine. European Journal of Cardiovascular Prevention and Rehabilitation, 2009, 16, 722-728.	3.1	17
70	Mortality, incidence of cardiovascular diseases, and educational level among the diabetic and non-diabetic populations in two large Italian cities. Diabetes Research and Clinical Practice, 2011, 92, 205-212.	1.1	17
71	Inappropriately high left ventricular mass in patients with type 2 diabetes mellitus and no overt cardiac disease. The DYDA study. Journal of Hypertension, 2011, 29, 1994-2003.	0.3	17
72	The under-use of statin in type 2 diabetic patients attending diabetic clinics in Italy. Nutrition, Metabolism and Cardiovascular Diseases, 2007, 17, 32-40.	1.1	16

#	ARTICLE	IF	CITATIONS
73	Incidence of hospitalization and mortality in patients with diabetic foot regardless of amputation: a population study. <i>Acta Diabetologica</i> , 2020, 57, 221-228.	1.2	16
74	Left ventricular dysfunction and outcome at two-year follow-up in patients with type 2 diabetes: The DYDA study. <i>Diabetes Research and Clinical Practice</i> , 2013, 101, 236-242.	1.1	15
75	The role of the care model in modifying prognosis in diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 11-16.	1.1	15
76	Normoalbuminuric kidney impairment in patients with T1DM: insights from annals initiative. <i>Diabetology and Metabolic Syndrome</i> , 2018, 10, 60.	1.2	15
77	Management of newly diagnosed patients with type 2 diabetes: what are the attitudes of physicians? A SUBITO!AMD survey on the early diabetes treatment in Italy. <i>Acta Diabetologica</i> , 2012, 49, 429-433.	1.2	14
78	Global cardiovascular risk management in different Italian regions: An analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2012, 22, 635-642.	1.1	14
79	Improving quality of care in people with Type 2 diabetes through the Associazione Medici Diabetologiâ€annals initiative: a longâ€term costâ€effectiveness analysis. <i>Diabetic Medicine</i> , 2014, 31, 615-623.	1.2	14
80	Global Cardiovascular Risk Assessment in Different Clinical Settings. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2009, 16, 55-63.	1.0	13
81	Use of Electronic Support for Implementing Global Cardiovascular Risk Management. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2010, 17, 37-47.	1.0	13
82	Five-Year Predictors of Insulin Initiation in People with Type 2 Diabetes under Real-Life Conditions. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-10.	1.0	13
83	Diabetes-specific variables associated with quality of life changes in young diabetic people: The type 1 diabetes Registry of Turin (Italy). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013, 23, 1031-1036.	1.1	12
84	Comparison of direct costs of type 2 diabetes care: Different care models with different outcomes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 717-724.	1.1	12
85	Incidence and correlated factors of beta cell failure in a 4-year follow-up of patients with type 2 diabetes: a longitudinal analysis of the BETADECLINE study. <i>Acta Diabetologica</i> , 2016, 53, 761-767.	1.2	12
86	Impact of Diabetes Mellitus on the Clinical Management of Global Cardiovascular Risk: Analysis of the Results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitization (EFFECTUS) Educational Program. <i>Clinical Cardiology</i> , 2011, 34, 560-566.	0.7	11
87	Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 3296-3302.	1.8	11
88	Long-term blood pressure variability, incidence of hypertension and changes in renal function in type 2 diabetes. <i>Journal of Hypertension</i> , 2020, 38, 2279-2286.	0.3	11
89	Changes in albuminuria and renal outcome in patients with type 2 diabetes and hypertension. <i>Journal of Hypertension</i> , 2018, 36, 1719-1728.	0.3	10
90	Beta cell stress in a 4-year follow-up of patients with type 2 diabetes: A longitudinal analysis of the <i>BetaDecline</i> Study. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e3016.	1.7	10

#	ARTICLE	IF	CITATIONS
91	Portrait of women with type 1 or type 2 diabetes of childbearing age attending diabetes clinics in Italy: the AMD-Annals initiative. <i>Acta Diabetologica</i> , 2018, 55, 193-199.	1.2	9
92	Could clinical inertia in part explain the unexpected association of insulin therapy with poorer cardiovascular outcomes in observational studies on diabetes?. <i>Diabetes Research and Clinical Practice</i> , 2011, 92, e47-e48.	1.1	8
93	Comment on: Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i> 2012;35:1364-1379. <i>Diabetes Care</i> , 2012, 35, e71-e71.	4.3	8
94	Secondary prevention of coronary artery disease in high-risk diabetic patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2003, 13, 238-243.	1.1	7
95	Self-Monitoring of Blood Glucose in Type 2 Diabetes: Steps toward consensus. <i>Diabetes Care</i> , 2007, 30, e105-e105.	4.3	7
96	An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy. High Blood Pressure and Cardiovascular Prevention, 2011, 18, 19-30.	1.0	7
97	From swab testing to health outcomes within the T2DM population: Impact of diabetes background on COVID19 progression. <i>Diabetes Research and Clinical Practice</i> , 2021, 180, 109021.	1.1	7
98	Antihyperglycemic treatment in patients with type 2 diabetes in Italy: the impact of age and kidney function. <i>Oncotarget</i> , 2017, 8, 62039-62048.	0.8	7
99	Determinants of good metabolic control without weight gain in type 2 diabetes management: a machine learning analysis. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001362.	1.2	6
100	To what extent is the new position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) "personalised"? <i>Diabetologia</i> , 2012, 55, 2853-2855.	2.9	5
101	Incretin-based therapy and risk of cholangiocarcinoma: a nested case-control study in a population of subjects with type 2 diabetes. <i>Acta Diabetologica</i> , 2020, 57, 401-408.	1.2	5
102	Prescription of Sulphonylureas among Patients with Type 2 Diabetes Mellitus in Italy: Results from the Retrospective, Observational Multicentre Cross-Sectional SUSCIPE (Sulphonyl_UreaS_Correct_Internal_Prescription_Evaluation) Study. <i>Diabetes Therapy</i> , 2020, 11, 2105-2119.	1.2	5
103	Hepatic fibrosis of any origin in a large population of type 2 diabetes patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 2887-2894.	1.1	5
104	Short Course of Insulin Treatment versus Metformin in Newly Diagnosed Patients with Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2018, 7, 235.	1.0	4
105	Effects of linagliptin on left ventricular DYsfunction in patients with type 2 DiAbetes and concentric left ventricular geometry: results of the DYDA 2 trial. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 8-17.	0.8	4
106	Factors associated with a rapid normalization of HbA1c in newly diagnosed type 2 diabetes patients seen in a specialist setting. <i>Acta Diabetologica</i> , 2013, 50, 81-87.	1.2	3
107	Cardiovascular Biomarkers, Cardiac Dysfunction, and Outcomes in Patients With Type 2 Diabetes: A Prospective, Multicenter Study. <i>Diabetes Care</i> , 2013, 36, e137-e138.	4.3	3
108	Results of the Adequacy of glycemiC Control in pAtients with type 2 Diabetes mEllitus treated with Metformin monotherapY at the maximal-tolerated dose (ACCADEMY) study. <i>Endocrine</i> , 2016, 52, 507-515.	1.1	3

#	ARTICLE	IF	CITATIONS
109	Effects of Dipeptidyl Peptidase-4 Inhibitor Linagliptin on Left Ventricular Dysfunction in Patients with Type 2 Diabetes and Concentric Left Ventricular Geometry (the DYDA 2â„ Trial). Rationale, Design, and Baseline Characteristics of the Study Population. <i>Cardiovascular Drugs and Therapy</i> , 2019, 33, 547-555.	1.3	3
110	Instructive lessons from the analysis of assistance in diabetes during the first phase of COVID-19 pandemic. <i>Acta Diabetologica</i> , 2022, 59, 861-864.	1.2	3
111	Impact of physiciansâ€™ age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control Training and Ultra Sensitisation Educational Programme. <i>International Journal of Clinical Practice</i> , 2011, 65, 649-657.	0.8	2
112	Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes. <i>BMC Nephrology</i> , 2018, 19, 347.	0.8	2
113	Clinical characteristics and patterns of care of newly diagnosed type 2 diabetic patients. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2007, 17, e31-e33.	1.1	1
114	The implementation of international standardization of glycated hemoglobin. A "red-letter-day" for glycated hemoglobin in Italy: 1/1/11. Italian Recommendations of GLAD Working Group (A1c delegates) <i>Tj ETQq0 Q18rgBT /Overlock 10</i>		